Secondary outcomes during follow-up
jaundice, cholangitis
RECURRENCE, RECURRENT CHOLANGITIS, CHOLANGITIS
At 7-day follow-up, in the mild cholangitis group, 31 (91.18%) patients treated with CSTS and 31 (90.91%) patients treated with MEPM achieved normal body temperature (Secondary outcomes during follow-up.AFC, age at first cholangitis; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; CSTS, cefoperazone sodium tazobactam sodium; DBIL, direct bilirubin; IQR, interquartile range; IVIG, intravenous immunoglobulin; LT, liver transplantation; Meropenem, MEPM; NLS, native liver survival; T, temperature; WBC, white blood cell count; γ-GT, gamma-glutamyl transferase.WBC, EUC, CRP, ALT, AST, γ-GGT, and DBIL were compared using independent samples In the mild cholangitis group, patients treated with MEPM had lower WBC than those treated with CSTS [7.65 (IQR: 5.80–8.30) vs. 8.27 (IQR: 6.80–9.98), At 1-month follow-up, the jaundice clearance rate in the mild cholangitis group was not different between those treated with CSTS and MEPM (CSTS, 81.82% vs. MEPM, 90.32%). There was no significant difference in NLS, relapse rate, ALT, AST, γ-GGT, and DBIL between the two groups (all At 3 and 6 months of follow-up, in the mild cholangitis group, there was no significant difference of NLS, recurrence rate, jaundice clearance rate, ALT, AST, γ-GGT, and DBIL between the patients treated with CSTS or MEPM (all At 7-day follow-up, no recurrent cholangitis was observed in the study population. At 1-month follow-up, the incidence of recurrent cholangitis was significantly lower in the mild cholangitis group than in the severe cholangitis group (4.69 vs. 28.57%, These results indicated that CSTS and MEPM treatment had similar outcomes in mild cholangitis at 6 months of follow-up, supporting CSTS as a first-line antibiotic for mild post-KPE cholangitis. Furthermore, in severe cholangitis, MEPM+IVIG improved liver function at 7 days and 1-month after enrollment. The results suggest that IVIG is an effective adjunctive treatment for severe post-KPE cholangitis to improve short-term clinical outcomes.